Trials / Active Not Recruiting
Active Not RecruitingNCT05954910
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
The Effectiveness and Safety of Polatuzumab in Real-World Clinical Practice Among Chinese Adult Patients With Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Registry Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Polatuzumab Vedotin | Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling. |
Timeline
- Start date
- 2023-08-25
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
- First posted
- 2023-07-20
- Last updated
- 2026-02-02
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05954910. Inclusion in this directory is not an endorsement.